Sildenafil for Treatment of Erectile Dysfunction in Men With Diabetes: A Randomized Controlled Trial | Urology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Centers for Disease Control and Prevention.  National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United StatesAtlanta, Ga: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 1997.
2.
NIH Consensus Development Panel on Impotence.  Impotence.  JAMA.1993;270:83-90.Google Scholar
3.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.  J Urol.1994;151:54-61.Google Scholar
4.
Saenz de Tejada I, Goldstein I. Diabetic penile neuropathy.  Urol Clin North Am.1988;15:17-22.Google Scholar
5.
Braunstein GD. Impotence in diabetic men.  Mt Sinai J Med.1987;54:236-240.Google Scholar
6.
McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence.  Diabetologia.1980;18:279-283.Google Scholar
7.
Whitehead ED, Klyde BJ. Diabetes-related impotence in the elderly.  Clin Geriatr Med.1990;6:771-795.Google Scholar
8.
Rundles RW. Diabetic neuropathy.  Medicine (Baltimore).1945;24:111-159.Google Scholar
9.
Rubin A, Babbott D. Impotence in diabetes mellitus.  JAMA.1958;168:498-500.Google Scholar
10.
Zemel P. Sexual dysfunction in the diabetic patient with hypertension.  Am J Cardiol.1988;61:27H-33H.Google Scholar
11.
Andersson KE, Wagner G. Physiology of penile erection.  Physiol Rev.1995;75:191-236.Google Scholar
12.
Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical stimulation cause relaxation of corpus cavernosum smooth muscle.  Biochem Biophys Res Commun.1990;170:843-850.Google Scholar
13.
Burnett AL. Role of nitric oxide in the physiology of erection.  Biol Reprod.1995;52:485-489.Google Scholar
14.
Burnett AL. Nitric oxide in the penis: physiology and pathology.  J Urol.1997;157:320-324.Google Scholar
15.
Boolell M, Allen MJ, Ballard SA.  et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.  Int J Impot Res.1996;8:47-52.Google Scholar
16.
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction.  N Engl J Med.1998;338:1397-1404.Google Scholar
17.
Price DE, Boolell M, Gepi-Attee S, Wareham K, Yates P, Gingell JC. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men.  Diabet Med.1998;15:821-825.Google Scholar
18.
National Diabetes Data Group.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.  Diabetes.1979;28:1039-1057.Google Scholar
19.
Fleiss J. The Design and Analysis of Clinical ExperimentsNew York, NY: John Wiley & Sons Inc; 1986:49-51.
20.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF).  Urology.1997;49:822-830.Google Scholar
21.
McCulloch DK, Hosking DJ, Tobert A. A pragmatic approach to sexual dysfunction in diabetic men: psychosexual counselling.  Diabet Med.1986;3:485-489.Google Scholar
22.
Whitehead ED. Diabetes-related impotence and its treatment in the middle-aged and elderly: Part II.  Geriatrics.1987;42:77-80, 85.Google Scholar
23.
Bell D, Cutter G, Hayne V, Lloyd L. Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for the treatment of erectile dysfunction in diabetic males.  Urology.1992;40:36-40.Google Scholar
24.
Seftel AD, Vaziri ND, Ni Z.  et al.  Advanced glycation end products in human penis.  Urology.1997;50:1016-1026.Google Scholar
Original Contribution
February 3, 1999

Sildenafil for Treatment of Erectile Dysfunction in Men With Diabetes: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Creighton Diabetes Center, Omaha, Neb (Dr Rendell); Harbor-University of California, Los Angeles Medical Center, Torrance (Dr Rajfer); Pfizer Central Research, Groton, Conn (Dr Wicker) and Sandwich, England (Dr Smith). A complete list of the members of the Sildenafil Diabetes Study Group appears at the end of this article.

JAMA. 1999;281(5):421-426. doi:10.1001/jama.281.5.421
Abstract

Context Erectile dysfunction is common in men with diabetes.

Objective To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes.

Design A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996.

Setting Patients' homes and 19 clinical practice centers in the United States.

Patients A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years).

Interventions Patients were randomized to receive sildenafil (n=136) or placebo (n=132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg, with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed.

Main Outcome Measures Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events.

Results Two hundred fifty-two patients (94%) completed the study (131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56%) of 131 patients in the sildenafil group reported improved erections compared with 13 (10%) of 127 patients in the placebo group (P<.001). The proportion of men with at least 1 successful attempt at sexual intercourse was 61% (71/117) for the sildenafil group vs 22% (25/114) for the placebo group (P<.001). Adverse events related to treatment were reported for 22 (16%) of 136 patients taking sildenafil and 1 (1%) of 132 patients receiving placebo. The most common adverse events were headache (11% sildenafil, 2% placebo), dyspepsia (9% sildenafil, 0% placebo), and respiratory tract disorder (6% sildenafil, 2% placebo), predominantly sinus congestion or drainage. The incidence of cardiovascular adverse events was comparable for both groups (3% sildenafil, 5% placebo).

Conclusion Oral sildenafil is an effective and well-tolerated treatment for erectile dysfunction in men with diabetes.

×